Cargando…

Management of High-Risk Localized Prostate Cancer

Traditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marciscano, Ariel E., Hardee, Matthew E., Sanfilippo, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206331/ https://www.ncbi.nlm.nih.gov/pubmed/22110494 http://dx.doi.org/10.1155/2012/641689

Ejemplares similares

Optimizing the Management of High-Risk, Localized Prostate Cancer
por: Sundi, Debasish, et al.
Publicado: (2012)

A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)
por: Wolfe, Sydney, et al.
Publicado: (2023)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)

What Is New in the Management of High-Risk Localized Prostate Cancer?
por: Wani, Mudassir, et al.
Publicado: (2023)

Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer
por: Qureshy, Sarah A., et al.
Publicado: (2023)

Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer
por: Makino, Tomoyuki, et al.
Publicado: (2021)

Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer
por: Iwamoto, Hiroaki, et al.
Publicado: (2022)

Is there an optimal management for localized prostate cancer?
por: Singh, Jaspreet, et al.
Publicado: (2010)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer
por: Imber, Brandon S., et al.
Publicado: (2020)

Role of noninvasive molecular imaging in determining response
por: Marciscano, Ariel E., et al.
Publicado: (2018)

HDR Brachytherapy in the Management of High-Risk Prostate Cancer
por: Masson, Susan, et al.
Publicado: (2012)

Focal Therapy in the Management of Prostate Cancer: An Emerging Approach for Localized Prostate Cancer
por: Nomura, Takeo, et al.
Publicado: (2012)

Very high risk localized prostate cancer: definition and outcomes
por: Sundi, Debasish, et al.
Publicado: (2013)

Future Prospects in the Diagnosis and Management of Localized Prostate Cancer
por: Tefekli, Ahmet, et al.
Publicado: (2013)

Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options
por: Zaorsky, Nicholas G., et al.
Publicado: (2020)

Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
por: Clark, Roderick, et al.
Publicado: (2022)

Prostate cancer screening and the management of clinically localized disease
por: Wilt, Timothy J, et al.
Publicado: (2013)

Editorial for the Special Issue on High-Risk Localized and Locally Advanced Prostate Cancer
por: Izumi, Kouji
Publicado: (2023)

Advances in Localized Prostate Cancer Management
por: Samadi, David B., et al.
Publicado: (2018)

The role of cystoprostatectomy in management of locally advanced prostate cancer: a systematic review
por: Yuan, Peng, et al.
Publicado: (2020)

Divorcing Diagnosis From Treatment: Contemporary Management of Low-Risk Prostate Cancer
por: Glass, Allison S., et al.
Publicado: (2013)

High-Intensity Focused Ultrasound (HIFU) in Localized Prostate Cancer Treatment
por: Alkhorayef, Mohammed, et al.
Publicado: (2015)

High-risk Locally Advanced Prostate Cancer: Multimodal Treatment Is the Key
por: Terlizzi, Mario, et al.
Publicado: (2022)

Primary Total Prostate Cryoablation for Localized High-Risk Prostate Cancer: 10-Year Outcomes and Nomograms
por: Chen, Chung-Hsin, et al.
Publicado: (2023)

Perspectives on the clinical management of localized prostate cancer
por: Nelson, Joel B
Publicado: (2014)

Treatment of Localized and Locally Advanced, High-Risk Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries
por: Khauli, Raja, et al.
Publicado: (2021)

Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer
por: van Oort, I. M., et al.
Publicado: (2008)

Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer
por: Choe, Kevin S., et al.
Publicado: (2010)

Future perspective of focal therapy for localized prostate cancer
por: O'Connor, Luke P., et al.
Publicado: (2021)

Neoadjuvant Therapy in High-Risk Prostate Cancer
por: Ashrafi, Akbar N., et al.
Publicado: (2020)

Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)
por: Marciscano, Ariel E., et al.
Publicado: (2023)

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
por: Brown, Gordon, et al.
Publicado: (2022)

Most of patients with localized prostate cancer will be treated in the future? | Opinion: No
por: Schulman, Ariel A., et al.
Publicado: (2017)

How Precisely Can Prostate Cancer Be Managed?
por: Zhuang, Liyan, et al.
Publicado: (2016)

Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US
por: Agrawal, Vishesh, et al.
Publicado: (2020)

Prostate-specific antigen kinetics in hypofractionated radiation therapy alone for intermediate- and high-risk localized prostate cancer
por: Lee, Tae Hoon, et al.
Publicado: (2023)

Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy
por: Sundi, Debasish, et al.
Publicado: (2019)

Surgical Delay and Pathological Outcomes for Clinically Localized High-Risk Prostate Cancer
por: Xia, Leilei, et al.
Publicado: (2020)

Personalized Management in Low-Risk Prostate Cancer: The Role of Biomarkers
por: Dijkstra, Siebren, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3qinj617mheui6mdugft77513h